Search research articles
Contact Us
Filters
Showing results (21-30 of 64) with videos related to
Page
of 7
Sort By:
Plos One
|
December 13, 2018
Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation
Kerstin Pohl, David P Nichols, Jennifer L Taylor-Cousar, et al.
Annals of the American Thoracic Society
|
August 19, 2020
Effect of Concomitant Azithromycin and Tobramycin Use on Cystic Fibrosis Pulmonary Exacerbation Treatment
Jonathan D Cogen, Anna V Faino, Frankline Onchiri, et al.
Journal of Managed Care & Specialty Pharmacy
|
December 28, 2023
The cost of simplifying treatments for cystic fibrosis: Implications of the SIMPLIFY trial
Laura S Gold, Ryan N Hansen, Nicole Mayer-Hamblett, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 8, 2021
Association Between Number of Intravenous Antipseudomonal Antibiotics and Clinical Outcomes of Pediatric Cystic Fibrosis Pulmonary Exacerbations
Jonathan D Cogen, Anna V Faino, Frankline Onchiri, et al.
Plos One
|
February 13, 2015
Mycobacterium abscessus morphotype comparison in a murine model
Lindsay J Caverly, Silvia M Caceres, Cori Fratelli, et al.
Annals of the American Thoracic Society
|
March 15, 2022
Clinical Outcomes of Antipseudomonal versus Other Antibiotics among Children with Cystic Fibrosis without <i>Pseudomonas aeruginosa</i>
Jonathan D Cogen, Anna V Faino, Frankline Onchiri, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
August 10, 2023
The impact of elexacaftor/tezacaftor/ivacaftor on fat-soluble vitamin levels in people with cystic fibrosis
Georgene E Hergenroeder, Anna Faino, Gracia Bridges, et al.
Free Radical Biology & Medicine
|
November 20, 2019
The thiocyanate analog selenocyanate is a more potent antimicrobial pro-drug that also is selectively detoxified by the host
Brian J Day, Preston E Bratcher, Joshua D Chandler, et al.
Radiology
|
April 24, 2008
Detection of simulated inflicted metaphyseal fractures in a fetal pig model: image optimization and dose reduction with computed radiography
Patricia L Kleinman, David Zurakowski, Keith J Strauss, et al.
Heliyon
|
April 29, 2024
Longitudinal improvements in clinical and functional outcomes following initiation of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis
Kadambari Vijaykumar, Hui Min Leung, Amilcar Barrios, et al.
Page
of 7
Search research articles
Search
Showing results (21-30 of 64) with videos related to
Sort By:
Page
of 7
Plos One
|
December 13, 2018
Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation
Kerstin Pohl, David P Nichols, Jennifer L Taylor-Cousar, et al.
Annals of the American Thoracic Society
|
August 19, 2020
Effect of Concomitant Azithromycin and Tobramycin Use on Cystic Fibrosis Pulmonary Exacerbation Treatment
Jonathan D Cogen, Anna V Faino, Frankline Onchiri, et al.
Journal of Managed Care & Specialty Pharmacy
|
December 28, 2023
The cost of simplifying treatments for cystic fibrosis: Implications of the SIMPLIFY trial
Laura S Gold, Ryan N Hansen, Nicole Mayer-Hamblett, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 8, 2021
Association Between Number of Intravenous Antipseudomonal Antibiotics and Clinical Outcomes of Pediatric Cystic Fibrosis Pulmonary Exacerbations
Jonathan D Cogen, Anna V Faino, Frankline Onchiri, et al.
Plos One
|
February 13, 2015
Mycobacterium abscessus morphotype comparison in a murine model
Lindsay J Caverly, Silvia M Caceres, Cori Fratelli, et al.
Annals of the American Thoracic Society
|
March 15, 2022
Clinical Outcomes of Antipseudomonal versus Other Antibiotics among Children with Cystic Fibrosis without <i>Pseudomonas aeruginosa</i>
Jonathan D Cogen, Anna V Faino, Frankline Onchiri, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
August 10, 2023
The impact of elexacaftor/tezacaftor/ivacaftor on fat-soluble vitamin levels in people with cystic fibrosis
Georgene E Hergenroeder, Anna Faino, Gracia Bridges, et al.
Free Radical Biology & Medicine
|
November 20, 2019
The thiocyanate analog selenocyanate is a more potent antimicrobial pro-drug that also is selectively detoxified by the host
Brian J Day, Preston E Bratcher, Joshua D Chandler, et al.
Radiology
|
April 24, 2008
Detection of simulated inflicted metaphyseal fractures in a fetal pig model: image optimization and dose reduction with computed radiography
Patricia L Kleinman, David Zurakowski, Keith J Strauss, et al.
Heliyon
|
April 29, 2024
Longitudinal improvements in clinical and functional outcomes following initiation of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis
Kadambari Vijaykumar, Hui Min Leung, Amilcar Barrios, et al.
Page
of 7